5 terminated, 3 completed. 7 Phase 3, 2 Phase 2.
By phase and status
Follow apaziquone: new trials by email Literature Review of apaziquone trials Research Report on apaziquone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
Qapzola, Placebo - Bladder Cancer | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 118 | 2017-08-04 | 2021-09-28 |
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Apaziquone, Placebo - Bladder Cancer | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 62 | 2015-10-09 | 2021-10-27 |
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Apaziquone, Placebo - Bladder Cancer | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 47 | 2012-01-01 | 2017-12-15 |
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
EO9 (Apaziquone), Placebo - Bladder Cancer | Phase 2 / Phase 3 | Terminated | Nippon Kayaku Co., Ltd. | 51 | 2011-11-01 | 2017-03-29 |
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Apaziquone, Placebo - Bladder Cancer | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 66 | 2011-07-01 | 2016-12-13 |
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Apaziquone, Placebo, TURBT - Bladder Cancer | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 812 | 2007-08-01 | 2017-11-13 |
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Apaziquone, Placebo, TURBT - Bladder Cancer | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 802 | 2007-04-01 | 2021-03-30 |
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Apaziquone - Bladder Neoplasms | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 53 | 2005-07-01 | 2012-06-14 |
Conditions studied
Urinary Bladder Neoplasms (8) · Non-Muscle Invasive Bladder Neoplasms (4) · Carcinoma in Situ (1)
Sponsors
Spectrum Pharmaceuticals, Inc (7) · Nippon Kayaku Co., Ltd. (1)
Countries
United States (6) · Canada (2) · Poland (2) · Czechia (1) · Japan (1) · Netherlands (1) · Slovakia (1) · South Korea (1)
Top investigators
Shanta Chawla, MD (3) · Show-Li Sun, MD (2) · Alfred Witjes, MD, Prof. (1) · Kees Hendricksen, MD (1) · Woo Ick Jang, M.D., Ph.D. (1) · Yoshihiro Nambu, M.D., Ph.D. (1)